Molecular efficacy evaluation of Agastya haritaki rasayana on chronic obstructive pulmonary disorder (COPD)

Evaluation of Pharmacokinetics, clinical efficacy and Innate Immunity response of T-cells count and Cytokine (IFN gamma/IL-2) on oral administration of Agastya haritaki rasayana in chronic obstructive pulmonary disorder (COPD) - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105780

Enrollment

Registered

2026-03-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 30-50 years age group of either sex with confirmed diagnosis of moderate to very severe COPD without any co morbidities.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Dementia, mental disorders, and reluctant partner, diabetis, Hypertension, Complicated with heart failure, Current respiratory disorders other than COPD

Design outcomes

Primary

Measure	Time frame
Dyspnea, Cough, Expectoration, Wheezing, Frequency of attack and Peak expiratory flow rate, Forced vital capacity, Forced expiratory volumTimepoint: 45 days	—

Secondary

Measure	Time frame
total leukocyte count, differential count of neutrophils, leukocytes, eosinophils etc, ESR, Hb%, total RBC and Absolute Eosinophil Count (AEC) conducted before and after treatment are also considered while assessing the clinical efficacy along with changes in T cell count, IFNs gamma/IL-2 assayTimepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Manjunath Ajanal

Rajiv Gandhi education society Ayurvedic medical college Hospital Ron. Gadag Abbhigeri road, Ron

manju.ajanal@gmail.com9036616510

Outcome results